The FDA's Pharmacy Compounding Advisory Committee voted on July 23–24 at the agency's White Oak campus to recommend six peptides for the 503A Bulks List, the roster of bulk drug substances that licensed pharmacies may legally compound. BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon each cleared narrow margins. Emideltide, proposed for insomnia and opioid withdrawal, failed 6–7. FDA scientific staff had recommended against all seven peptides under review—fourteen recommendations in total, covering both chemical forms of each compound—citing insufficient safety and efficacy data, as documented by the American Journal of Managed Care.

The vote is non-binding. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk substance must appear on the Bulks List before a pharmacist can prepare it as a custom prescription, and none of the six peptides currently meets that threshold. FDA must accept the recommendation, publish a proposed rule, accept public comments, and issue a final rule before any compounding pharmacy gains legal authority. Regulatory attorneys tracking the docket told Mondaq that the notice-and-comment sequence typically requires eight to twelve months. Until that process concludes, the peptides remain illegal to compound and continue circulating as unregulated "research chemicals."

Evidence the panel voted past

FDA's briefing documents identified a single human trial for BPC-157, the most widely used of the six: a small 2005 study published only as a conference abstract, with no Phase 3 randomized data for ulcerative colitis or any other indication. The agency's adverse-event database recorded three reports tied to compounded BPC-157, including one patient whose shortness of breath led to an emergency-room visit. Chemical characterization in the nomination was inconsistent enough that FDA could not confirm whether a pharmacy would prepare the acetate or arginate salt form, an ambiguity that determines which compound a patient actually receives and that mirrors the formulation questions examined in this comparison of BPC-157 salt forms.

TB-500, KPV, and MOTS-c have no published human studies at any dose for any indication. Semax, marketed for cognitive and neurological complaints, showed signs in FDA's assessment of raising bleeding risk and triggering a dopamine response the agency described as "typically induced by drugs of abuse." Across all six recommended peptides, staff counted zero completed Phase 3 trials.

Appointments, financial ties, and a pending HHS action

Eight of the committee's fourteen voting members were appointed in April and May 2026, four to ten weeks before the meeting. The Associated Press reported that several new appointees hold financial ties to peptide businesses. Medscape's coverage identified six of those spring appointees as affiliated with clinics offering peptide therapies, with two others carrying separate industry connections. One member's term began roughly one week after FDA issued a June 8 warning letter to Maximus Health for claiming its compounded weight-loss drugs matched approved medications, and six weeks before that member voted on the peptide docket.

During public comment, one panelist expressed concern that the committee was "responding to market induced demand rather than a decision based in science," NPR reported from the meeting. The vote tallies reflected the split: BPC-157, KPV, and TB-500 each passed 8–6 with one abstention; MOTS-c cleared 7–5; Semax passed 8–5; epitalon 7–4.

The vote landed five months after HHS Secretary Robert F. Kennedy Jr. announced plans on February 27, 2026, to move fourteen peptides—including BPC-157 and TB-500—from Category 2 restrictions to Category 1 status, which would permit compounding with a prescription. That reclassification has not been finalized. The advisory panel's recommendation and the pending HHS action address overlapping compounds through separate regulatory mechanisms, and neither alone authorizes a pharmacy to prepare these substances.

Rulemaking and the next docket

The recommendation now sits with FDA's Center for Drug Evaluation and Research, which may accept, modify, or reject it. No proposed rule has appeared in the Federal Register. The distinction between 503A individual-prescription compounding and 503B outsourcing-facility production will determine how these substances reach patients if listing proceeds, a separation detailed in this breakdown of 503A versus 503B regulations. Neither pathway opens for these peptides until rulemaking concludes.

FDA has scheduled the next Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to evaluate five additional peptides: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor.